Vera Therapeutics, Inc.
VERA
$37.25
$4.2512.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 155.38% | 125.97% | 91.79% | 72.35% | 29.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 85.97% | 101.34% | 89.71% | 63.87% | 33.82% |
| Operating Income | -85.97% | -101.34% | -89.71% | -63.87% | -33.82% |
| Income Before Tax | -87.49% | -102.40% | -86.06% | -58.50% | -30.75% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -87.49% | -102.39% | -86.06% | -58.50% | -30.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.49% | -102.39% | -86.06% | -58.50% | -30.75% |
| EBIT | -85.97% | -101.34% | -89.71% | -63.87% | -33.82% |
| EBITDA | -85.77% | -101.16% | -90.54% | -137.89% | -89.25% |
| EPS Basic | -53.30% | -62.35% | -46.52% | -19.86% | 9.65% |
| Normalized Basic EPS | -53.30% | -62.35% | -46.56% | -19.89% | 9.55% |
| EPS Diluted | -53.30% | -62.35% | -46.52% | -19.86% | 9.65% |
| Normalized Diluted EPS | -53.30% | -62.35% | -46.56% | -19.89% | 9.55% |
| Average Basic Shares Outstanding | 22.90% | 24.95% | 27.13% | 29.60% | 33.13% |
| Average Diluted Shares Outstanding | 22.90% | 24.95% | 27.13% | 29.60% | 33.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |